Personally, I wish they would not release any data, until the analysis is completed. Previously, when they released pieces of the analysis, from the clinical trials, it seemed to have hurt the share price, gave the shorts ammunition and put the management in the position of having to walk back some of their earlier claims. Additionally, slow roll out of the data, leads to claims of cherry picking. I'm happy to wait for the finished product.